DBV Technologies Bolsters Cash Reserves but Accelerates Cash Burn Ahead of U.S. Launch of Viaskin Peanut
French biopharmaceutical company DBV Technologies closed the fiscal year 2025 with mixed signals: a financial stronghold with cash reserves multiplied by six over one year, but an R&D engine consuming more resources. This tension reflects the company's strategy: to accumulate financial ammunition to fund the introduction of Viaskin Peanut in the U.S. market, at the cost of increasing operational losses. A bet on the future that demands flawless execution.
Financial Fortification Amidst Increased Cash Burn
As of December 31, 2025, DBV Technologies reported cash reserves of $194.2 million, up from just $32.5 million a year earlier. This dramatic increase resulted from a private placement (PIPE) launched in 2025 and an 'At-The-Market' program which generated $276.2 million in financing flows. An additional $94 million was received in January 2026 from the exercise of warrants, bringing the total resources mobilized to over $370 million in twelve months. Concurrently, the net loss for the year deepened to $147.0 million from $113.9 million in 2024, a deterioration of 29%. The loss per share was established at $1.05, a slight improvement compared to $1.17 in 2024, reflecting a diluted share base.
Strategic R&D Spending and Preparation for U.S. Launch
The deterioration in net income is explained by an increase in research and development expenses of $27.3 million, placing this function at the heart of the execution strategy. General and administrative expenses (SG&A) also increased by $4.6 million, reflecting additional staff recruited and market studies undertaken to prepare for the commercial launch of Viaskin Peanut in the U.S. pending regulatory approval. These infrastructure expenses demonstrate the company's determination to turn its therapeutic candidate into a commercial product. Research activities also benefited from a more generous research tax credit, with operational revenues reaching $5.6 million compared to $4.2 million in 2024. Cash flows used for operating activities amounted to $121.2 million in 2025, up from $104.5 million in 2024, signaling an accelerated cash burn of 16%.
Financial Outlook and Regulatory Challenges
The management estimates that it has sufficient resources to fund its operations until the second quarter of 2027, providing a visibility of fifteen to eighteen months. This projection is based on current forecasts and explicitly excludes any additional expenditure related to other programs than Viaskin Peanut, as well as any licensing or acquisition operations. DBV Technologies acknowledges that its estimates may prove inaccurate and that cash burn could be faster than anticipated. The central challenge for investors remains the regulatory approval of Viaskin Peanut in the U.S. and the company's ability to convert this regulatory status into revenue streams before the depletion of its cash reserves.
